NDA/PLA REVIEWS MAY NOT BE DELAYED DUE TO GENERAL DATA INTEGRITY ISSUES UNDER PhRMA FDA REFORM PLAN; OTC OFFICE WOULD RETURN TO REVIEW ALL SWITCHES